Icon PLC (NASDAQ:ICLR)
| Market Cap | 12.24B-12.0% |
| Revenue (ttm) | 8.25B+2.0% |
| Net Income | 328.88M-58.6% |
| EPS | 4.26-56.2% |
| Shares Out | 76.57M |
| PE Ratio | 37.25 |
| Forward PE | 13.45 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 156,992.11 |
| Open | 161.62 |
| Previous Close | 164.08 |
| Day's Range | 159.40 - 162.22 |
| 52-Week Range | 66.57 - 211.00 |
| Beta | 1.24 |
| Analysts | Buy |
| Price Target | 173.82(+8.76%) |
| Earnings Date | Oct 28, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About ICLR
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$ICLR stock is featured in our Insider Score Rankings, Congress Trading, and Insider Trades datasets.
→ All Stock ListsCongress Trading
Recent trades of ICLR by members of U.S. Congress
| Politician | Type | Traded |
|---|---|---|
| Kevin HernHouse / R | Sale$15.00K – $50.00K | Aug 14, 2026 |
| Kevin HernHouse / R | Sale$15.00K – $50.00K | Aug 13, 2026 |
| Kevin HernHouse / R | Sale$100.00K – $250.00K | Mar 5, 2026 |
| Kevin HernHouse / R | Sale$100.00K – $250.00K | Mar 4, 2026 |
| Kevin HernHouse / R | Sale$1.00K – $15.00K | Jan 31, 2023 |
| Kevin HernHouse / R | Sale$1.00K – $15.00K | Jan 30, 2023 |
| Kevin HernHouse / R | Purchase$100.00K – $250.00K | May 18, 2021 |
| Kevin HernHouse / R | Purchase$1.00K – $15.00K | Jul 27, 2020 |
Recently reported changes in ICLR holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ICLR's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ICLR Estimated quarterly lobbying spending
Source: U.S. Senate LDA
ICLR Revenue by Segment or Geography
Source: SEC EDGAR (10-Q/10-K)
U.S. Patents
New ICLR patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ICLR from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ICLR
| ETF | Est. Holding Size |
|---|---|
| DFSVU.S. Small Cap Value Portfolio ETF Class Shares | $115.31M |
| GCSHGuggenheim Funds Trust - Guggenheim Ultra Short Income ETF | $100.60M |
| DFATDimensional - US Targeted Value ETF | $36.14M |
| PIEQPrincipal Exchange-Traded Funds - Principal International Equity ETF | $25.58M |
| DFACDimensional - US Core Equity 2 ETF | $21.03M |
| DFASDimensional - US Small Cap ETF | $18.57M |
Estimated from each fund’s disclosed top holdings × AUM
ICLR Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from ICLR’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score